IceCure adds West Cancer Center as 400-patient ChoICE study expands ProSense breast cryoablation evidence
West Cancer Center has received IRB approval to join IceCure’s 400-patient ChoICE post-market study of ProSense in women aged 70 and older with small, biologically low-risk breast cancers.